Noticias de EDIT_US
Noticias del mercado
Últimas noticias sobre EDIT_US — 208 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medici
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock By Investing.com
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock
Editas Medicine CFO Amy Parison sells $1,253 in stock
Editas Medicine (EDIT) CFO logs small automatic tax-related share sale
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com
Editas Medicine CFO Amy Parison sells $1,253 in stock
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock By Investing.com
Editas Medicine (EDIT) CSO sells 731 shares under automatic tax-cover plan
Editas Medicine (EDIT) CEO logs automatic, tax-related share sale
Una nueva terapia basada en CRISPR, EDIT-401, demostró reducciones duraderas del 90 % en el colesterol LDL y la Lp(a) en estudios preclínicos, dirigidos a pacientes de alto riesgo cardiovascular. Los ensayos clínicos comenzarán en Australia en 2024, y se esperan datos de primera línea para 2027. Basado en Editas Medicine, Inc. [ED…
Editas (EDITAR) informó ganancias hace 30 días. Qué
Página 1 de 11
